Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

65 results about "Carbamoyl phosphate synthetase" patented technology

Carbamoyl phosphate synthetase catalyzes the ATP-dependent synthesis of carbamoyl phosphate from glutamine (EC 6.3.5.5) or ammonia (EC 6.3.4.16) and bicarbonate. This enzyme catalyzes the reaction of ATP and bicarbonate to produce carboxy phosphate and ADP. Carboxy phosphate reacts with ammonia to give carbamic acid. In turn, carbamic acid reacts with a second ATP to give carbamoyl phosphate plus ADP.

Pyrimidine nucleoside high-yielding strain and carbamyl phosphate synthetase adjusting site thereof

The invention belongs to the technical field of enzyme engineering, and concretely relates to a pyrimidine nucleoside high-yielding strain and a carbamyl phosphate synthetase adjusting site thereof. The invention provides a pyrimidine nucleoside production Bacillus subtilis mutant strain and a carbamyl phosphate synthetase encoding gene. A key regulation site related to carbamyl phosphate synthetase end product feedback inhibition is defined, and provides reference for breeding of later pyrimidine nucleoside high-yielding strains. The Bacillus subtilis mutant strain allows the output of fermentation process produced nucleoside pyrimidine uridine to reach 14-16g / L, and has substantially improved tolerance to different pyrimidine nucleoside structure analogs.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY

131I labeled anti-tumor humanized monoclonal antibody 1E2 and use thereof

The invention provides an anti-lung cancer human resource monoclonal antibody 1E2 marked by <131>I. The human resource 1E2 antibody, Na <131>I and chloramine T are used as raw materials, and purified 1E2 antibody marked by the <131>I can be prepared by using the chloramine T method, wherein, the human source 1E2 antibody is obtained by taking paracanser lymph nodes of a non-small cell lung cancer patient, extracting total RNA in lymph node tissues, and then a phage antibody library containing the 1E2 antibody is obtained by using the constructing technology of the phage antibody library, and the phage antibody 1E2 is adsorbed by using a carbamyl phosphate synthetase antigen, and a human source 1E2 antibody which is specific to the carbamyl phosphate synthetase is finally obtained by washing, screening and amplifying. The invention applies radiation immunity treatment technology, combines advantages of radionuclide and anti-tumor cell human source monoclonal antibody to one, improves the targeting ability and curative effect of medicines to tumor cells, reduces side effects and poor immune reactions, and is wider in application range and suitable for treatments of the non-small cell lung cancer of each stage.
Owner:CHONGQING MEDICAL UNIVERSITY

Function and application of thymidylate synthetase CAD (carbamoyl-phosphate synthetase II, aspartate transcarbamylase and dihydroorotase) gene in treating fatty liver and type-II diabetes mellitus

ActiveCN104069511AImprove fatty liverImprove type 2 diabetesPeptide/protein ingredientsMetabolism disorderIntraperitoneal routeStaining
The invention discloses a function and application of thymidylate synthetase CAD (carbamoyl-phosphate synthetase II, aspartate transcarbamylase and dihydroorotase) genes in treating fatty liver and type-II diabetes mellitus, and belongs to the field of gene functions and application. Functions of CAD genes are studied by a high-fat diet (HFD) induced model, and results discover that the levels of body weight and fasting blood-glucose of a CAD gene knock-out mouse in an HFD group are higher than those of a WT (Wild Type) mouse in a control group; glucose tolerance tests by intraperitoneal injection discover that the tolerance of the CAD gene knock-out mouse on glucose is remarkably weakened; the integral liver appearance, liver weight, liver/weight ratio and lipid component pathological staining result of the mouse indicate that the fatty liver disease of the CAD knock-out mouse in the HFD group is remarkably severe, the lipid accumulation is remarkably increased, and these results indicate that CAD gene knock-out can remarkably deteriorate fatty liver and type-II diabetes mellitus. Regarding the effects of CAD, the CAD can be used for preparing medicaments for preventing, relieving and/or treating fatty liver and/or type-II diabetes mellitus.
Owner:武汉惠康基因科技有限公司

Ammonia (ammonia ion) determination method and ammonia (ammonia ion) diagnosis/determination kit

The invention relates to a method for determining the content of ammonia (ammonia ion) by using technologies of enzymatic colorimetry and enzyme-linked immunosorbant assay, and compositions of a reagent. A technical principle for determination is that the determination is finished according to a series of catalytic reactions of ammonia kinase, carbamyl phosphate synthetase and fatty acid synthase. The invention also relates to an ammonia (ammonia ion) diagnosis / determination kit. The determination method provided by the invention is high in sensitivity and small in error, so that the determination method and the kit can be widely applied to clinical medical / food inspection.
Owner:SUZHOU ANJ BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products